Amarin (AMRN) Drops Most in 7 Months as FDA Makes No Determination on Vascepa
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corp Plc (Nasdaq: AMRN) has fallen as much as 14.6 percent Wednesday following an 8-K filing earlier updating the FDA's status on Vascepa. The drop is the largest Amarin shares have seen in about seven months.
From the filing: "Based on information available to Amarin as of the filing of this report, including communication with the FDA on October 9, 2012, the FDA has not yet made a determination with respect to regulatory exclusivity for Vascepa."
For more, click here.
Shares are off of session lows, but still down around 10.4 percent. This is the lowest Amarin's been since last June.
From the filing: "Based on information available to Amarin as of the filing of this report, including communication with the FDA on October 9, 2012, the FDA has not yet made a determination with respect to regulatory exclusivity for Vascepa."
For more, click here.
Shares are off of session lows, but still down around 10.4 percent. This is the lowest Amarin's been since last June.
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
